Medicaid expansion among previously uninsured individuals has led to improved healthcare access. However, considerably lower reimbursement rates of Medicaid have raised concerns on the unintended consequence of lower utilization of life-saving therapies and inferior outcomes compared with private insurance. We examined the rates of revascularization and in-hospital mortality among Medicaid beneficiaries versus privately insured individuals hospitalized with STsegment-elevation myocardial infarction (STEMI).
M
edicaid is the largest health insurance program in the United States covering 73 million lives with $553 billion in spending in fiscal year 2016. 1 Medicaid expansion under the Affordable Care Act (ACA) has enabled >15 million of previously uninsured individuals to obtain healthcare coverage. 2, 3 Furthermore, expansion of Medicaid has been associated with significantly improved healthcare access. 2, 4, 5 Medicaid reimbursement to the hospitals and providers is often lower compared with private insurance. The reimbursement gap between Medicaid and private insurance has further widened during the past 2 decades. 6 In principle, the reimbursement rates should have no effect on how health care is provided in general and especially for emergent medical conditions, such as ST-segment-elevation myocardial infarction (STEMI). However, the differences in reimbursement rates have raised concerns for the unintended consequence of lower utilization of life-saving therapies in Medicaid beneficiaries compared with privately insured individuals. 7 A previous study has shown that having insurance, including Medicaid, is associated with better outcomes in STEMI than self-pay. 8 The disparities in STEMI management and in-hospital outcomes among Medicaid and privately insured patients nationally across the United States are not well understood. We, therefore, sought to examine the differences in management and outcomes between Medicaid beneficiaries versus privately insured STEMI hospitalizations as a proxy for understanding the impact of reimbursement gap across the 2 groups.
METHODS

Data, Analytic Methods, and Research Materials Transparency
The National Inpatient Sample (NIS) database is publically available online at the following web-based link: https:// www.distributor.hcup-us.ahrq.gov/. Additional information on data, analytic methods, and study materials will be made available to other researches for purpose of reproducing the results or replicating the procedure on request.
Data Source
We used data from the NIS-the largest publically available all-payer database. 9 The details of the NIS have been published previously. [10] [11] [12] In brief, the NIS was developed by the Healthcare Cost and Utilization Project (HCUP) and is sponsored by the Agency for Healthcare Research and Quality (AHRQ). 9 From 2012 onward, NIS comprises of a 20% stratified sample of discharges from all of >4000 HCUP/AHRQ participating hospitals that represents >95% of the US hospitalizations. 9 Before 2012, the sampling strategy consisted of 100% inpatient discharges from a 20% random sample of the participating hospitals. 9, 13 From October 2015 onward, the NIS consisted the International Classification of Diseases (ICD), Tenth Revision, Clinical Modification diagnostic and procedural codes instead of Ninth Revision codes. To eliminate inherent bias because of difference in the sampling and coding strategy over time, we restricted our study population to contemporary STEMI hospitalizations from January 2012 to September 2015. Because the NIS is a publically available deidentified national dataset, these analyses were exempt from the Institutional Review Board approval of the University of Alabama at Birmingham.
Study Design
This is an observational study utilizing the administrative claims database, which was conducted and reported in accordance with the Reporting of Studies Conducted Using Observational Routinely Collected Heath Data statement (Table I in the Data  Supplement). 14 The ICD, Ninth Revision, Clinical Modification (ICD-9-CM) codes 410.0 to 410.8 (excluding 410.7) were used to identify hospitalizations with principal discharge diagnosis of STEMI from 2012 through 2015. 15, 16 The NIS contains data on the expected primary payers as Medicare (includes fee-for-service and Medicare advantage), Medicaid (includes fee-for-service and managed care), private insurance, self-pay, no charge, other, or missing. Hospitalizations with Medicaid or private insurance as primary payer were included in the study cohort. To avoid dual Medicaid-and Medicare-eligible individuals, we excluded hospitalizations aged ≥65 years. We excluded STEMI hospitalizations with age <18 years. We also excluded hospitalizations that resulted in transfer to another acute care facility or those with discharge disposition of left against medical advice.
The baseline characteristics of STEMI hospitalizations were identified using the NIS variables. Race was categorized into 3 levels: whites, blacks, and others. Socioeconomic status (SES) was categorized as the quartiles of median household income based on the residential ZIP code of each hospitalization. 17 The 
WHAT IS KNOWN
WHAT THE STUDY ADDS
• Medicaid beneficiaries with ST-segment-elevation myocardial infarction had lower rates of coronary revascularization and thrombolysis, lower utilization of drug-eluting stents, and higher rates of in-hospital mortality compared with privately insured individuals.
• Our study highlights the need to identify and better understand the reasons behind the disparities in ST-segment-elevation myocardial infarction outcomes by insurance status.
Elixhauser comorbidity index derived from ICD-9-CM codes and diagnosis-related groups 18 and previously published ICD-9-CM codes were used to identify individual comorbidities for our study (Table II in 
Outcomes
All study outcomes were identified a priori (ie, identified ahead of time by examining the previous literature). The primary outcomes were the rates of coronary revascularization and in-hospital mortality after STEMI hospitalizations in Medicaid beneficiaries versus privately insured individuals. The secondary outcomes were rates of coronary angiography, thrombolysis use, invasive hemodynamic support, length of stay, and cost of hospitalization. Procedure codes for coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting), thrombolysis (including thrombolysis within 24 hours before hospitalization), and invasive hemodynamic support (intra-aortic balloon pump, percutaneous left ventricular assist device, 13 or extra corporeal membrane oxygenation) were identified using appropriate ICD-9-CM codes ( Table III in the Data Supplement). The total hospital charges were converted to costs using HCUP/AHRQ cost-to-charge ratio that was based on hospital accounting reports from the Centers for Medicare and Medicaid Services.
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Statistical Analysis
Statistical analyses were performed using SAS 9.4 (SAS Institute, Inc, Cary, NC). National estimates were generated using discharge weights provided by the sponsor (HCUP/ AHRQ). 20 For unadjusted analysis, univariable logistic regression model was applied to the data from entire study cohort to estimate odds ratio (OR) for the outcomes of interest comparing Medicaid versus private insurance groups. All tests were 2 sided, and level of significance was set at a P value of <0.05. All analyses were conducted accounting for survey nature (SURVEYMEANS, SURVEYLOGISTIC, and SURVEYFREQ), clustering of admissions within a hospital (HOSP_NIS), weighting (DISCWT), and stratification (NIS_STRATUM) of the NIS and followed the expert consensus methodology statement to conduct research using the NIS database (Table IV in 
Propensity-Matched Analyses
Because of the differences in demographics, socioeconomic, clinical, and hospital characteristics between Medicaid beneficiaries and privately insured individuals, a propensity score was developed using a nonparsimonious multivariable logistic regression model with automated stepwise selection. Baseline hospitalization level characteristics (age, sex, race, SES, and individual Elixhauser comorbidities, including drug and alcohol abuse), STEMI acuity (cardiac arrest and cardiogenic shock), and hospital-level characteristics (hospital region, rural or urban location, and hospital size) were used to generate a propensity score. Insurance type (Medicaid versus private) was treated as a dependent variable in this model. STEMI hospitalizations with a similar propensity score in both groups were matched using a 1:1 scheme without replacement using the nearest neighbor matching algorithm with a caliper width equal to the 0.1 of the SD of the logit of the propensity score. Absolute standardized differences were estimated for all baseline characteristics to assess prematch and postmatch imbalances between groups. 22 Absolute standardized difference <10% for a given variable indicates relatively small imbalance between the groups and was considered acceptable matching. 23 To estimate difference in the outcomes between matched cohorts, paired comparison was performed with the use of McNemar test for categorical variables and Wilcoxon signed-rank test for continuous variables. Additionally, ORs with 95% CIs were generated to compare the primary and secondary outcomes from these matched cohorts.
To examine the robustness of differences in rates of study outcomes between Medicaid beneficiaries and privately insured individuals, a sensitivity analysis was conducted by creating a propensity score-matched cohort among STEMI hospitalizations without in-hospital mortality.
In a secondary analysis utilizing full study cohort, we also tested whether revascularization is a significant mediator of association of insurance status with in-hospital mortality. We further examined what proportion of the effect of insurance status on mortality was mediated by difference in revascularization rates between the 2 insurance groups after accounting for the baseline characteristics. This mediation analysis was performed using STATA/SE 15.1 (StataCorp LP, College Station, TX).
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RESULTS
A total of 214 190 STEMI hospitalizations that met study criteria were identified from January 2012 through September 2015. Among these hospitalizations, 42 645 and 171 545 were identified as having Medicaid and private insurance, respectively ( Figure 1 ). Baseline characteristics for STEMI hospitalizations stratified by primary payer status are shown in Table 1 . Compared with privately insured individuals, Medicaid beneficiaries with STEMI tended to be younger (mean age, 51.5 versus 53.8 years), women (30.5% versus 20.6%), and more nonwhite (41.3% versus 25.5%) ( Table 1) . A higher proportion of STEMI hospitalizations with Medicaid was in the lowest quartile of SES compared with those with private insurance (39.4% versus 21.8%). Comorbidities and substance abuse were higher in Medicaid beneficiaries compared with privately insured individuals. Rates of cardiac arrest and cardiogenic shock during STEMI hospitalizations were also higher among Medicaid hospitalizations compared with private insurance (Table 1) . Medicaid hospitalizations were in greater proportion from Northeast and West hospital regions and large rural and urban teaching hospitals compared with private insurance (Table 1) .
Unadjusted Analysis
In unadjusted analysis, Medicaid as a primary payer was associated with lower rates of coronary revascularization (OR, 0.67; 95% CI, 0.65-0.70; P<0.001) and higher in-hospital mortality (OR, 
Propensity-Matched Analyses
There were 40 870 propensity-matched STEMI hospitalizations in each of the 2 groups (Medicaid and private insurance). The absolute standardized difference of baseline characteristics, including age, sex, race, SES, comorbidities, rates of cardiac arrest, and cardiogenic shock, and hospital characteristics between these 2 groups were <10%, indicating balance between the groups (Figure 2 ).
Primary Outcomes Revascularization
In the propensity score-matched cohort, STEMI hospitalizations of Medicaid beneficiaries had significantly lower odds of coronary revascularization compared with privately insured individuals (OR, 0.80; 95% CI, 0.76-0.84; P<0.001; Table 2; Figure 3 ). Of note, the absolute differences in the rates of revascularization were small (≈2%). Rates of PCI (82.9% versus 85.0%; P<0.001) were lower in Medicaid beneficiaries compared with privately insured individuals. Rates of coronary artery bypass grafting (4.3% versus 4.2%; P=0.60) were similar between both groups. Despite extensive matching on demographics, SES, various comorbidities, and severity of STEMI hospitalization that includes presence of cardiogenic shock or cardiac arrest, Medicaid hospitalizations with STEMI were significantly less likely to receive drug-eluting stents (52.8% versus 64.2%; P<0.001) and more likely to receive bare-metal stents (24.3% versus 15.8%; P<0.001) or percutaneous transluminal coronary angioplasty alone without stenting (5.0% versus 4.2%; P<0.001) as compared with private insurance (Table 2) .
In-Hospital Mortality
In the propensity score-matched cohort, odds of inhospital mortality were 35% higher in Medicaid beneficiaries with STEMI compared with privately insured Figure 3 ).
Secondary Outcomes Coronary Angiography
The rate of coronary angiography was lower among Medicaid beneficiaries compared with private insurance with STEMI (92.3% versus 93.0%; P<0.001; Table 2 ).
Thrombolysis
Utilization of thrombolysis was significantly lower in
Medicaid beneficiaries compared with private insurance with STEMI (4.5% versus 5.4%; P<0.001; Table 2 ; Figure 3) .
Invasive Hemodynamic Support
The rates of invasive hemodynamic support with the mechanical devices were similar between Medicaid beneficiaries and privately insured individuals with STEMI (10.0% versus 9.7%; P=0.18) consistent with similar rates of cardiogenic shock in matched cohort (Table 2; Figure 3 ).
Length of Stay and Cost of Hospitalization
The median length of stay was similar between the 2 groups: 3 days (interquartile range, 2-5 days) for Medicaid versus 3 days (interquartile range, 2-4 days) for private insurance, P=0.08. The median cost of hospitalization was higher in Medicaid beneficiaries compared with private insurance with STEMI ($19 617 versus $18 837; P<0.001; Table 2; Figure 3 ).
Secondary Analysis
After accounting for baseline characteristics, revascularization was a significant mediator of the association between insurance status and in-hospital mortality (P<0.001). A total of 22.7% (95% CI, 12.5%-33.0%) of the effect of insurance status on mortality was mediated by differential rates of revascularization in the 2 insurance groups.
Sensitivity Analysis of STEMI Hospitalizations Excluding Cases of InHospital Mortality
In the propensity-matched cohort of 38 810 STEMI hospitalizations in each group without in-hospital mortality, the rates of revascularization (90.4% versus 92.5%), thrombolytic use (4.6% versus 5.3%), and coronary angiography (93.3% versus 93.8%) remained significantly lower among Medicaid beneficiaries with STEMI compared with privately insured individuals (Tables VI and VII in the Data Supplement).
DISCUSSION
In this large nationwide retrospective study of STEMI hospitalizations from January 2012 through September 2015, Medicaid insurance was found to be associated with a 2% lower rate of coronary revascularization procedures and 1.2% higher rate of in-hospital mortality after STEMI compared with private insurance, despite extensive matching on demographics, SES, comorbidities, acuity of STEMI, and hospital-level characteristics. Medicaid beneficiaries with STEMI were more likely to receive bare-metal stents, whereas those with private insurance were more likely to receive drug-eluting stents for coronary revascularization. We also noted 17% lower odds of thrombolytic use in Medicaid beneficiaries admitted with STEMI compared with privately insured individuals. The rates of invasive hemodynamic support were similar between Medicaid beneficiaries and private insurance with STEMI. The median length of stay was also similar, although a higher median cost of STEMI hospitalization was observed in Medicaid beneficiaries compared with privately insured individuals.
The data from 1990s have suggested that payer status is associated with use of invasive cardiac procedures and outcomes after myocardial infarction with lower rates of revascularization and higher in-hospital mortality in Medicaid beneficiaries. 25, 26 A more recent singlestate study showed underutilization of PCI for STEMI in Medicaid beneficiaries compared with private insurance. 7 However, the association of Medicaid insurance status with rates of revascularization during hospitalization for STEMI in a contemporary national US cohort is not known. This is especially important because the Medicaid eligibility and its administration has evolved over time and varies widely from state to state. Further, the key question of the association of Medicaid insurance with rates of in-hospital mortality outcomes after STEMI under contemporary management strategy has remained unexplored. Our study showed that in a nationally representative dataset, rates of revascularization for STEMI are lower, whereas in-hospital mortality after STEMI hospitalization is higher in Medicaid beneficiaries compared with private insurance. It is alarming that despite decades of health reform, and advancements in STEMI revascularization strategies, our investigation showed persistent disparities in utilization of revascularization for STEMI and in-hospital outcomes by payer status.
There are several potential explanations for the lower rates of coronary angiography, revascularization, and thrombolysis among STEMI hospitalizations between Medicaid beneficiaries compared with privately insured individuals. First, Medicaid patients with STEMI may have higher burden of comorbidities precluding them from artery opening interventions. However, we matched groups extensively based on multiple comorbidities, including cardiovascular, renal, and liver disease, as well as the presence of coagulation disorder. Further, matching was also done based on age, sex, race, and SES because these conditions may track comorbidities in Medicaid population that may not be accounted for in adjustment. However, there may be unmeasured and residual confounding that may partly explain these differences. Second, traditionally fewer proportions of Data were presented as n (%) or median (IQR). CABG indicates coronary artery bypass grafting; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; IQR, interquartile range; NA, not available; OR, odds ratio; PCI, percutaneous coronary intervention; pLVAD, percutaneous left ventricular assist device; PTCA, percutaneous transluminal coronary angioplasty; and STEMI, ST-segment-elevation myocardial infarction.
Medicaid beneficiaries are thought to be good candidates for dual antiplatelet therapy because of actual or perceived lower rates of medication adherence. This may also lead to lower rates of PCI and higher rates of bare-metal stent use when PCI is done in Medicaid beneficiaries. However, previous studies have indicated that insurance status may not affect compliance to the dual antiplatelet therapy. 27, 28 Third, it has been shown previously that Medicaid beneficiaries were more likely to present to a non-PCI-capable facility with higher rates of interfacility transfer. 7 To avoid bias resulting from this, we excluded all STEMI hospitalizations that were transferred out to another facility. In addition, we matched on hospital-level characteristics and performed a sensitivity analysis after excluding hospitalizations resulted in mortality. However, the lower rates of revascularization among Medicaid beneficiaries still persisted.
In-hospital mortality after STEMI hospitalization was higher in Medicaid beneficiaries compared with privately insured individuals, despite extensive risk adjustment. Although the differences in the rates of revascularization were small, we observed that a significant proportion of the effect of insurance status on mortality was mediated by revascularization such that 23% of higher odds of mortality among Medicaid beneficiaries with STEMI was attributable to lower rates of revascularization. Prospective studies are needed to further understand the additional mechanisms of lower revascularization rates and higher in-hospital mortality in Medicaid beneficiaries hospitalized with STEMI.
We also observed that despite lower rates of coronary angiography, revascularization, and thrombolysis use, and similar median length of stay, the cost of hospitalization was slightly higher for Medicaid beneficiaries compared with private insurance. This may be because of higher in-hospital mortality with increased associated costs that may offset any savings from lower revascularization rates. Higher cost of hospitalization may also result from a higher downstream cost of deferring revascularization procedures, such as need for more prolonged systemic anticoagulation.
The aforementioned observations can also be explained by Medicaid's diverse payment system. Healthcare providers typically get timely payments for health care delivered to the privately insured. However, the Medicaid payment system is complex and different from private insurances. 29 Medicaid payments to healthcare providers are divided into 2 parts: base payment and supplemental payment. 29 Medicaid base payment for healthcare services provided to the beneficiaries is typically set by state Medicaid agencies. Additional supplemental payments related to healthcare services may or may not be provided to the hospitals. Historically, Medicaid pays ≈90% of the cost incurred to the hospitals, whereas private insurances typically remunerate ≈144% of the cost of the service provided by the hospital. 29, 30 Before the implementation of ACA, hospitals were able to sustain their financial operations by pooling Medicaid and private insurance payments in one basket called as the Hospital Payer Mix. 29 However, after the execution of ACA, hospitals are getting a higher number of Medicaid beneficiaries, which has distorted the hospital payer mix. 29, 30 These aforementioned changes may have created additional financial constraints for the hospitals/providers providing care to Medicaid beneficiaries. Therefore, the link between the impact of ACA changes and STEMI outcomes needs to be formally examined in future studies. All values for the outcomes were generated from propensity score-matched private insurance (green) vs Medicaid (red) cohorts. Data were presented in percentage (left, y axis), days (length of stay; left, y axis), and dollars (cost of hospitalization; right, y axis). P values are for comparison of Medicaid vs private insurance.
Our investigation has significant public health implications. Congress recently approved the Tax Cuts and Jobs Act of 2017. This act mandates federal spending cuts on the government-run programs, especially Medicare, Medicaid, and ACA subsidies during a period of next 10 years. 31 The Center on Budget and Policy Priorities and Congressional Budget Office have estimated that there will be ≈29% federal spending cuts to Medicaid and the ACA programs. 31, 32 These spending cuts to Medicaid may further exacerbate the disparities in quality of health care and in-hospital outcomes for Medicaid beneficiaries with STEMI that were found in this study. Therefore, we urge policymakers to reconsider cuts to Medicaid or to allocate additional funding for cardiovascular emergency care, such as for hospitalizations with STEMI.
Limitations
This study has several limitations. The administrative databases, such as the NIS, are prone to the potential miscoding among diagnoses and procedural codes. However, when available, we used validated codes from literature or variables provided by HCUP/AHRQ to identify the ICD-9-CM codes for a particular diagnosis or procedure. The data in NIS are at hospitalization level and not patient level where there may be >1 hospitalization per patient. Additionally, the information on SES in the NIS is based on the median household income derived from ZIP code rather than individual income, which limits our ability to assess SES. Because the data were from administrative inpatient discharge database, there may be unmeasured and residual confounding that may partly explain the observed differences in outcomes. The NIS lacks information on type of Medicaid (managed care versus not), variation in Medicaid coverage (because state information is lacking), angiographic findings, door-to-balloon time, and ventricular function. Procedural complications, such as hospitalacquired infections and surgical site infections, could account for the observed differences in outcomes. Future studies incorporating these covariates may further the understanding on differences in the in-hospital management strategies and outcomes between Medicaid and private insurance. However, because the NIS is a large nationally representative database, it allows generalizability of findings with potential implications for healthcare policy.
CONCLUSIONS
In this nationally representative data, Medicaid beneficiaries hospitalized for STEMI had lower utilization of coronary revascularization and higher rates of in-hospital mortality compared with privately insured individuals. Additional studies to identify and understand the reasons behind the disparities in STEMI outcomes by insurance status are needed. Findings of low drug eluting stent use among Medicaid beneficiaries with STEMI also warrants additional research in future. Whether instilling additional federal funds to improve Medicaid versus private insurance reimbursement ratio will ameliorate the disparities remains to be tested as well. Dedicated efforts on customizing healthcare reforms by (1) increasing transparency around policy-making decisions and the overall process, (2) restructuring reimbursement policies for life-threating conditions and life-saving procedures independently, (3) increasing the supplemental payments to solidify Medicaid reimbursement, and (4) timeliness of supplemental payments to hospitals and healthcare providers to avoid distorting the payer mix are few possible solutions to improve these disparities.
